Statement of Principles concerning peritoneal adhesions (Reasonable Hypothesis) (No. 9 of 2025)

The instrument revolves around a small set of statutory and clinical concepts, set out and defined within the instrument itself. The operative medical definition is in subsection 7(2). Peritoneal adhesions are characterised by three points: they are acquired, permanent, and consist of abnormal fibrous connections following an abnormal inflammatory reaction of the peritoneum (s7(2)(a)). The instrument expressly includes encapsulating peritoneal sclerosis (s7(2)(b)) and excludes congenital adhesions (s7(2)(c)). A note attached to the definition records that adhesions may be asymptomatic or produce a range of clinical problems such as bowel obstruction, dyspareunia, infertility, obstetric complications, abdominal pain, and difficulty in subsequent abdominal surgery, but that note is descriptive rather than normative.

Causation is approached through the statutory test of whether a "reasonable hypothesis" has been raised connecting the condition or death to relevant service. Section 9 operationalises that test by listing the specific antecedent factors that, if present, are sufficient as a minimum to raise the reasonable hypothesis (s9 opening). The listed factors fall into several clinical and intervention-based categories:

• prior peritonitis and specific intra‑abdominal inflammatory diseases (appendicitis, cholecystitis, diverticulitis, endometriosis, inflammatory bowel disease, pancreatitis, pelvic inflammatory disease), each requiring occurrence at least three days before clinical onset (s9(1)-(2));
• intra‑abdominal or pelvic surgery and penetrating abdominal trauma entering the peritoneal cavity, again with the three‑day timing (s9(3)-(4));
• ablative radiotherapy where the abdominopelvic region was in the field (s9(5));
• infective agents involving the peritoneal cavity including bacterial, fungal or Echinococcus granulosus infection, and perforation of a hollow viscus into the peritoneal cavity (s9(6)-(7));
• procedures and prostheses: peritoneal dialysis for at least six months, intraperitoneal chemotherapy with specified agents, ventriculoperitoneal or peritoneovenous shunts, hernia mesh insertion at site, retained surgical sponge (s9(10)-(18), (22)-(24));
• oncological and cystic causes: primary or secondary malignant neoplasm involving the peritoneum, ruptured ovarian dermoid cyst (s9(13)-(14));
• pharmacological and inflammatory causes: practolol use for at least one year, peritoneal sarcoidosis at time of clinical onset (s9(25)-(26)).

Most antecedent factors require a minimum interval of at least three days before "clinical onset" to be relevant (s9). Clinical onset is used throughout but is not defined in this instrument; accordingly, its application depends on the evidentiary material in each claim. For peritoneal dialysis the instrument sets a longer exposure threshold: at least six months duration before clinical onset (s9(10)). For practolol the instrument requires an exposure period of at least one year (s9(25)). Specified chemotherapeutic agents for intraperitoneal chemotherapy are listed by name (cisplatin, oxaliplatin, carboplatin, 5‑fluorouracil, mitoxantrone (mitozantrone), mitomycin C) (s9(11)).

The instrument also clarifies that when a listed factor is itself an injury or disease covered by another Statement of Principles under subsection 196B(2) of the VEA, the factors in that other Statement apply according to its terms (s11). The Schedule supplies key definitional anchors that the instrument relies on: MRCA and VEA acronyms, the statutory categories of "relevant service" (operational, peacekeeping, hazardous, British nuclear test defence, warlike, non‑warlike), and the meaning of "terminal event" for death determinations (Schedule definitions).

Finally, the instrument references ICD‑10‑AM codes (K66.0, N73.6, N99.4) as commonly used codings for the condition but states that for the purposes of this Statement of Principles the meaning is the statutory definition in subsection 7(2) (s7(3)). The ICD reference is therefore ancillary and not determinative of the legal definition.

The instrument operates in the veterans' entitlements and MRCA administrative space and so primarily affects three groups directly: claimants (veterans and former members), statutory decision-makers and advisers, and medical evidence-holders. Section 5 sets the application: the instrument applies to claims to which section 120A of the VEA or section 338 of the MRCA applies. Those statutory provisions concern compensation or entitlements claims linked to service. The Schedule defines "relevant service" as the spectrum of operational, peacekeeping, hazardous, British nuclear test defence service (under the VEA), and warlike or non‑warlike service (under the MRCA). Therefore the population whose claims will be assessed by reference to this Statement comprises persons whose service falls into those statutory categories.

Decision-makers within the Department of Veterans' Affairs and any decision body that applies the VEA or MRCA will use this Statement to test causation. The Repatriation Medical Authority made the Statement under s196B(2) VEA and sets out the medical view the decision-makers are required to apply; s8 records that the Authority is of the view that there is sound medical‑scientific evidence that peritoneal adhesions can be related to relevant service. The instrument therefore affects the medical advisers and case officers who apply RMA Statements in adjudications.

Medical practitioners, hospitals and allied health providers are also affected in practice because the presence or absence of the listed factors will depend on clinical records and histories. To establish that a listed factor existed and met the timing thresholds (for example surgery, peritonitis, dialysis duration, drug history, intraperitoneal chemotherapy with specific agents), claimants will typically need documentary evidence from clinicians and facilities. Although the instrument does not create a duty on providers, it changes the evidentiary demands placed on claimants and thus increases the practical value of accurately maintained surgical notes, operation reports, dialysis treatment records, oncology treatment records, and pharmaceutical histories.

Legal representatives and advocates working on veterans' claims are affected because the Statement provides the checklist for establishing a "reasonable hypothesis" for causation in peritoneal adhesions cases. For factors that reference a condition covered by another Statement of Principles, s11 requires those other Statements to be applied; consequently, claim preparation may require collating records relevant to more than one Statement.

Less directly affected are manufacturers and suppliers involved in the listed exposures: suppliers of hernia mesh, manufacturers of practolol (noting that practolol is implicated subject to the one‑year exposure threshold), providers of peritoneal dialysis equipment and supplies, and institutions that administer intraperitoneal chemotherapy. The instrument does not regulate these entities, but their products and services are implicated evidentially in claims.

Finally, beneficiaries in death cases are affected because s7(4) treats death from peritoneal adhesions as encompassing death from a terminal event or condition that was contributed to by the adhesions. The Schedule defines terminal event broadly to include proximate or ultimate causes such as pneumonia, respiratory or circulatory failure and cessation of brain function. This shapes death claims and the evidence needed for death‑related entitlement determinations.

This Statement of Principles does not itself create statutory duties, criminal offences, or private rights of action. Its operative effect is normative within the statutory framework: it prescribes the medical factors that decision-makers must treat as satisfying the minimum evidentiary threshold for raising a reasonable hypothesis that peritoneal adhesions, or death from them, are related to relevant service.

For claimants, the right implicated is the right to have their claim assessed against the RMA's Statement when making a claim under section 120A of the VEA or section 338 of the MRCA (s5). Practically, to secure a favourable administrative finding on causation they must show at least one of the factors in section 9 existed and that the existence of that factor is related to the person's relevant service (s9; s10(1)). Thus the claimant's burden is to adduce evidence that a listed antecedent factor occurred and that it is attributable to relevant service. The instrument prescribes timing thresholds for most factors (typically at least three days before clinical onset) and explicit duration thresholds for some exposures (peritoneal dialysis at least six months, practolol for at least one year), so a claimant must produce evidence meeting those temporal criteria.

For decision-makers, the Statement supplies a statutory medical view that is to be applied in adjudication. Section 8 records the RMA's view of sound medical‑scientific evidence; under the VEA framework Statements made by the RMA are the medical material advisers use to determine whether a reasonable hypothesis exists. Decision-makers must therefore apply the factors in section 9 and the definitions in section 7 when assessing causation in the relevant claims. Where a listed factor is itself the subject of another Statement of Principles, section 11 directs that the factors in that other Statement apply in accordance with its terms. This creates a duty on decision-makers to cross-reference and apply multiple Statements where appropriate.

Administratively, decision-makers will need to verify temporal relationships: dates of surgery, dates of infection or peritonitis, commencement and duration of peritoneal dialysis, dates and agents used in intraperitoneal chemotherapy, dates of trauma entering the peritoneal cavity, dates of implantation of shunts or mesh, timing and duration of practolol therapy, and diagnosis of peritoneal sarcoidosis at clinical onset. The instrument references ICD‑10‑AM codes but states that for the purposes of this Statement the statutory definition in subsection 7(2) controls (s7(3)). Accordingly the decision-maker must not treat ICD codes as determinative where the statutory definition differs.

The Statement defines death from peritoneal adhesions to include death from a terminal event or condition that was contributed to by the adhesions (s7(4)), and the Schedule supplies the meaning of "terminal event" (Schedule). This affects rights in death claims: beneficiaries will need to establish not only that peritoneal adhesions existed and were related to service but also that those adhesions contributed to the terminal event that caused death.

There are no express obligations in the instrument placed on third parties to provide information; however, the practical implication for claimants is a need to obtain and present medical and service records sufficient to demonstrate that a listed factor occurred and was service‑related. The text does not prescribe a standard of proof beyond the statutory "reasonable hypothesis" threshold, but section 9 makes clear that the presence of at least one listed factor is the minimum evidentiary requirement to meet that threshold.

The Statement of Principles is an administrative, not a penal, instrument. The text contains no criminal sanctions, civil penalties, or enforcement mechanisms directed at private parties. It functions as a medical‑legal instrument within the veterans' entitlements system: its enforcement occurs through the administrative decision processes governed by the VEA and the MRCA.

Operationally, the consequence of the Statement is that decision-makers must apply its factors when determining whether a claimant has raised a reasonable hypothesis that peritoneal adhesions or death from them are related to relevant service (s5, s8-s11). The instrument therefore affects eligibility determinations and the outcome of claims for entitlements, rehabilitation or compensation. Any adverse outcome resulting from a decision informed by this Statement is subject to the review and appeal mechanisms established in the VEA and the MRCA, but those review pathways are outside the instrument and not detailed here.

There is no provision in the Statement for penalties for non-compliance by employers, medical practitioners, hospitals, suppliers, or claimants. The text likewise imposes no reporting or record‑keeping obligations. The only legal consequence set out is repeal of the prior Statement (No. 3 of 2016) where that earlier instrument is replaced as the operative Statement of Principles for peritoneal adhesions claims (s4).

Enforcement in practice therefore rests with administrative adjudication and with the quality and sufficiency of medical and service evidence supplied by or obtained for claimants. Where a decision-maker finds that the claimant has not established a relevant factor or the requisite relationship to relevant service, the outcome will be administrative denial or reduction of entitlements. The Statement itself provides no mechanism for imposing fines or other sanctions on clinicians or institutions for record deficiencies or late disclosure.

Finally, the Schedule’s definition of "terminal event" is relevant to death claims because it shapes which proximate or ultimate causes of death can be treated as contributed to by peritoneal adhesions (Schedule). There is no penalising language tied to the determinations of causation of death. Any corrective legal action arising from a disputed decision would follow existing VEA and MRCA review and appeal channels rather than any enforcement provision in this Statement.

The Statement is issued under subsection 196B(2) of the Veterans' Entitlements Act 1986 and explicitly links to the VEA and the MRCA throughout its provisions (s3, s5, Schedule). Its principal legal role is to operate within those statutes' decision-making processes: section 5 limits its application to claims for which section 120A of the VEA or section 338 of the MRCA applies. Consequently, determinations under the VEA and MRCA that rely on the RMA's Statements must treat this instrument as the operative medical standard for peritoneal adhesions.

Section 11 governs interaction with other Statements of Principles made under subsection 196B(2) of the VEA. If a factor set out in section 9 refers to an injury or disease that is already the subject of another Statement of Principles, then the factors in that other Statement apply according to their terms. This creates an integrated legal framework where multiple RMA Statements may be engaged in a single claim. For example, intra‑abdominal surgery or appendicitis listed in section 9 may themselves be the subject of other Statements; in such cases cross-application is mandated by s11.

The instrument makes a limited interaction with diagnostic coding systems: subsection 7(3) notes that peritoneal adhesions attract ICD‑10‑AM codes K66.0, N73.6 and N99.4 but provides that for the purposes of the Statement the statutory definition in subsection 7(2) controls. This means that while hospital coding may assist in identifying relevant medical records, the legal meaning within the VEA/MRCA causation assessment is the instrument’s textual definition, not a mere ICD code assignment.

Because the instrument sets thresholds for temporal relationships and durations (for example three days, six months, one year), it will interact with evidentiary rules and processes under the VEA and MRCA governing how clinical onset is determined and how service records are assessed. The instrument does not define "clinical onset"; therefore, that term must be interpreted in accordance with established doctrines and evidentiary practice under the VEA and MRCA. Decision-makers may need to refer to other parts of the VEA or MRCA or to case law interpreting the statutory "reasonable hypothesis" threshold and the concept of clinical onset, but those materials are outside the present instrument.

The Schedule defines "relevant service" by reference to categories under the VEA and the MRCA. That links the application of the Statement to determinations about the characterisation of an individual’s service under those Acts. If service is not established as "relevant service" under the VEA or MRCA, this Statement will not apply to the claim.

Finally, the repeal provision (s4) interacts temporally with the corpus of RMA Statements: claims assessed after commencement will use this instrument in place of the 2016 Statement. Any transitional or retrospective application is governed by the underlying adjudicative statutes (VEA and MRCA) rather than by the Statement itself.

The instrument records its own immediate amendment history succinctly. It is made and dated 17 December 2024 (document text header and signature block) and expressly commences on 28 January 2025 (s2). Section 4 effects repeal of the prior Statement of Principles concerning peritoneal adhesions (Reasonable Hypothesis) (No. 3 of 2016), which was Federal Register of Legislation No. F2016L00004. The repeal is categorical: the 2016 Statement made under subsections 196B(2) and (8) of the VEA is repealed, so from the commencement date No. 9 of 2025 replaces No. 3 of 2016 as the operative Statement for peritoneal adhesions claims (s4).

No other amendments, schedules or transitional arrangements are included in the text. The instrument does not provide an express transitional provision dealing with claims lodged but not finally determined as of commencement; the operational consequence is that decision-makers will apply the new Statement from its commencement date for claims to which the statutory application provisions otherwise extend. Any question of retrospective application or the treatment of claims that straddle the repeal and commencement dates will depend on administrative guidance and the governing statutes (VEA and MRCA), not on text within this instrument.

The Schedule acts as a definitional annex and consolidates key term definitions used throughout the Statement (MRCA, peritoneal adhesions cross‑reference, relevant service categories, terminal event, VEA). The instrument notes ICD‑10‑AM editions and effective dates for coding reference (s7(4) cross-referencing the Tenth Edition, effective date 1 July 2017), but reiterates that the statutory definition controls (s7(3)). The only explicit historical note in the instrument is the repeal of the 2016 Statement; no amendment history prior to 2016 is recorded in the text.

Signatures and dates in the header and signature block indicate the Repatriation Medical Authority’s formal adoption on 17 December 2024. The instrument does not annex any explanatory memorandum, medical literature citations, or version-tracking beyond the repeal of the 2016 Statement. Any policy or evidentiary rationale for changes compared with the 2016 instrument is not set out in the text and would need to be sought in the RMA's external materials or departmental explanatory materials, which are not part of this instrument.

The instrument itself contains no litigation history. It is a Statement of Principles made by the Repatriation Medical Authority under subsection 196B(2) of the VEA and does not reference any completed or ongoing judicial or tribunal proceedings. The text does not cite cases, dispute outcomes, judicial interpretations, or appellate decisions.

From the instrument alone one cannot infer whether the elements listed in section 9 have been the subject of litigation or whether the repeal and replacement of the 2016 Statement were driven by legal challenges. The Statement records the RMA's view that "there is sound medical‑scientific evidence" that peritoneal adhesions and death from them can be related to relevant service (s8), but that is a scientific claim manifested in the Statement and not a record of any litigation.

Where adjudicative disputes arise about whether a claimant has met the "reasonable hypothesis" threshold by reference to this Statement, those disputes will be resolved through the existing review and appeal mechanisms under the VEA and the MRCA. This could include administrative reconsideration, merits review and judicial review processes available under those Acts. The instrument does not document past judicial rulings on the interpretation of "reasonable hypothesis", "clinical onset", timing thresholds, or the evidentiary standards applicable to the factors listed; any such jurisprudence lies outside the text and must be located in the case law of the tribunals and courts that decide veterans' entitlements matters.

Practitioners preparing litigation or review materials will therefore need to combine this Statement with the procedural and jurisprudential materials of the VEA and MRCA review pathways. The Statement provides the substantive medical checklist for peritoneal adhesions causation but does not itself record how tribunals have applied similar Statements in contested proceedings. The absence of litigation references in the instrument means that users must search external records for precedents applying prior peritoneal adhesions Statements or interpreting comparable RMA Statements of Principles.

Several practical and legal pitfalls arise from the instrument's precise language and structure. These are matters that commonly cause disputes or evidentiary gaps in claims and that decision-makers and representatives should watch for.

1. Definition controls over ICD codes. Subsection 7(3) notes that while peritoneal adhesions attract specified ICD‑10‑AM codes, "in applying this Statement of Principles the meaning of peritoneal adhesions is that given in subsection (2)." That means an ICD code alone does not meet the statutory definition; adjudicators must apply the textual definition in s7(2). A hospital discharge summary with an ICD code but no description demonstrating acquired permanent fibrous connections caused by an abnormal inflammatory reaction will be insufficient in itself without supporting clinical detail.

2. Timing thresholds are specific and non‑uniform. Most antecedent factors require occurrence at least three days before "clinical onset" (s9(1)-(9), (11)-(15), (17)-(18), (22)-(24)). For peritoneal dialysis, the required duration is at least six months before clinical onset (s9(10)). For practolol the required duration is at least one year (s9(25)). Failure to tie the date of the antecedent exposure to the date of clinical onset in evidence will frequently be decisive against a claimant, so precise dating is essential.

3. Clinical onset is used but not defined. The instrument repeatedly uses the phrase "clinical onset" without a statutory definition. That leaves room for dispute over what event constitutes onset for the purposes of the timing thresholds. In practice, onset may be defined by symptom start, first clinical presentation, imaging confirmation, or operative findings; the instrument does not decide that question. Parties and decision-makers will therefore need to establish what they regard as clinical onset based on the medical records and accepted evidentiary practice under the VEA and MRCA.

4. Exclusion of congenital adhesions. The statutory definition excludes congenital peritoneal adhesions (s7(2)(c)). Where clinical records reference congenital adhesions or a congenital origin is plausible, claimants must provide evidence demonstrating that the adhesions were acquired and resulted from an abnormal inflammatory reaction rather than congenital anomalies.

5. Cross-application with other Statements. Section 11 requires application of other Statements where a listed factor is itself the subject of another Statement of Principles. Practically this means claim preparation may need to address the requirements of multiple RMA Statements. Failure to identify that a factor is covered by another Statement and to collate the requisite evidence under that other Statement may leave a claim incomplete.

6. Death claims require contribution to a terminal event. Subsection 7(4) extends the concept of "peritoneal adhesions" to include death from a terminal event or condition contributed to by the adhesions, and the Schedule defines terminal event comprehensively. However, claimants or representatives must show contribution to the terminal event; a mere presence of adhesions at death may not be enough without evidence that they contributed to the proximate or ultimate cause of death.

7. Specified chemotherapeutic agents and named exposures. The instrument requires intraperitoneal chemotherapy with specified agents for the factor in s9(11) to apply. If records show chemotherapy but do not specify intraperitoneal route or agent, the factor may not be met. Similarly, peritoneovenous or ventriculoperitoneal shunts, peritoneal dialysis, hernia mesh insertion at the site of subsequent adhesions, and retained surgical sponge are all individually listed; evidence must align with the description.

8. Practolol is listed with a one-year exposure threshold. Practolol is historically notable as an implicated pharmacological agent; the instrument requires at least one year of practolol before clinical onset (s9(25)). Incomplete medication histories or reliance on patient recollection without pharmacy or prescribing records can be vulnerable evidence.

9. Infective agents named. The instrument lists Echinococcus granulosus specifically among infections involving the peritoneal cavity (s9(6)). Documentation of the infective agent will therefore matter where infection is relied upon.

10. Note descriptors are not normative. The instrument contains explanatory notes (for example about symptoms and ICD codes). Those notes are descriptive and not dispositive of the statutory meaning; practitioners should not conflate notes with operative provisions.

Each of these points is grounded in the instrument’s wording and affects evidentiary strategy and adjudicative outcomes. The common theme is that precise, time‑stamped medical and service documentation are essential because the instrument ties entitlements to narrowly specified antecedent factors and temporal relations.

Compliance in this context means preparing a claim or making an administrative decision that faithfully applies the Statement's operative provisions. The instrument places evidentiary work on claimants and evidentiary scrutiny on decision-makers; the practical steps below follow directly from the text.

1. Identify relevant service. Before the Statement can apply, the claimant's service must fall within the "relevant service" definitions in the Schedule: operational, peacekeeping, hazardous or British nuclear test defence service under the VEA, or warlike or non‑warlike service under the MRCA (Schedule). Obtain service records, personnel files, deployment orders or other official documentation to establish the category of service.

2. Establish the condition falls within the statutory definition. Provide clinical evidence demonstrating that the peritoneal adhesions are acquired, permanent, abnormal fibrous connections between abdominal organs or between abdominal organs and the parietal peritoneum resulting from an abnormal inflammatory reaction (s7(2)(a)). If the claim relates to encapsulating peritoneal sclerosis include diagnostic and histopathological reports showing that manifestation (s7(2)(b)). Ensure that congenital origins are ruled out in records where relevant (s7(2)(c)).

3. Demonstrate at least one section 9 factor and the timing. Collate precise clinical records proving that one of the antecedent factors existed and met the timing or duration thresholds:

   • For peritonitis and the enumerated inflammatory diseases (appendicitis, cholecystitis, diverticulitis, endometriosis, inflammatory bowel disease, pancreatitis, pelvic inflammatory disease) obtain dated hospital notes, imaging, operative reports, pathology reports, discharge summaries and treating clinician statements that pin the diagnosis to specific dates at least three days before clinical onset (s9(1)-(2)).
   • For intra‑abdominal or pelvic surgery or penetrating abdominal trauma, obtain operation notes, theatre records, emergency department records, ambulance or incident reports and imaging that show the procedure or trauma entered the peritoneal cavity and the date relative to clinical onset (s9(3)-(4)).
   • For ablative radiotherapy, obtain oncology treatment records demonstrating the abdominopelvic region was in the radiation field and the dates (s9(5)).
   • For infections and perforations, secure microbiology, imaging and surgical reports specifying the infective process and timing (s9(6)-(7)).
   • For peritoneal dialysis demonstrate treatment duration of at least six months with dialysis unit records, prescription records or clinic notes (s9(10)).
   • For intraperitoneal chemotherapy, obtain oncology infusion records specifying agent and route; ensure the agent is one of the listed chemotherapeutic agents (s9(11)).
   • For shunts, mesh insertion, retained sponges, obtain operative and device insertion records and any subsequent imaging or complications notes (s9(15)-(18)).
   • For practolol exposure, obtain prescribing records, pharmacy dispensing history or medical notes confirming at least one year of use before clinical onset (s9(25)).
   • For peritoneal sarcoidosis, obtain histopathology, imaging and treating physician notes confirming diagnosis at clinical onset (s9(26)).

4. Define and document clinical onset. Because "clinical onset" is not defined in the instrument, identify and document the event you adopt as clinical onset for the claim: first reported symptom, first presentation to medical services for symptoms attributable to adhesions, imaging or operative confirmation. Have treating clinicians provide an opinion linking the chosen onset marker to the timing thresholds in section 9.

5. For death claims, document contribution to a terminal event. If the claim concerns death, assemble the death certificate, coronial findings if any, hospital notes, and treating clinician opinions that explain how the peritoneal adhesions contributed to the proximate or ultimate cause of death. Use the Schedule's definition of "terminal event" when framing the medical argument (Schedule).

6. Address overlapping Statements. If a factor invoked in section 9 is itself covered by another Statement of Principles, obtain and apply the evidence that Statement requires, because section 11 makes those other Statements applicable. Identify and collect the medical documentation relevant to the other Statement(s).

7. Prepare contemporaneous service linkage evidence. For factors that must be "related to the relevant service" (s10(1)), establish how the antecedent condition or exposure connects to service: for example, surgery or trauma that occurred on deployment, dialysis initiated during service, exposure to radiotherapy or intraperitoneal chemotherapy while in service, or practolol prescribed and taken during service. Service medical records and deployment health records will be central.

8. Use treating clinicians’ opinions where medical issues are complex. While the Statement supplies the medical checklist, complex causal links between service exposures and peritoneal adhesions or contribution to death may require medical opinion letters translating clinical records into causation opinions referring explicitly to the factors in section 9 and the timing thresholds.

9. For decision-makers: apply the Statement textually. When reviewing a claim, check that at least one factor in section 9 is established and that it is related to the claimant’s relevant service (s9; s10). If a listed factor is covered by another Statement, apply that Statement's factors (s11). Do not substitute ICD coding for the statutory definition (s7(3)).

10. Maintain documentary precision. Because the Statement ties entitlements to discrete factors and temporal thresholds, avoid vague documentation, unspecific dates, or uncorroborated recollections. The instrument anticipates determinations based on precise medical and service documentation.

Following these steps aligns claim preparation and adjudication with the instrument’s operative text and reduces risk of evidentiary deficiency arising from the precise requirements in section 9 and the Schedule.